Rafael Holdings, Inc. (RFL)

Market Cap	106.60M +114.1%
Revenue (ttm)	980,000 +33.9%
Net Income	-32.55M
EPS	-0.67
Shares Out	52.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	361,464
Open	2.050
Previous Close	2.060
Day's Range	1.950 - 2.100
52-Week Range	1.120 - 3.960
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About RFL

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Typ...

• Industry: Real Estate Services
• Sector: Real Estate
• Founded: 2017
• Employees: 23
• Stock Exchange: NYSE
• Ticker Symbol: RFL
• Website: https://www.rafaelholdings.com

Financial Performance

In fiscal year 2025, Rafael Holdings's revenue was $917,000, an increase of 43.96% compared to the previous year's $637,000. Losses were -$30.52 million, -11.30% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 18, 2026

Data Sources Report a data error